Another Twist on ADCs

Researchers at Johns Hopkins University have developed a new twist on antibody-drug-conjugates (ADCs): a drug related to the plant poison thapsigargin, coupled to a peptide that binds to prostate-specific membrane antigen (PSMA), which is not really prostate-specific, but instead is expressed on endothelial cells in the microenvironment of many solid tumors. Thapsigargin is a poison that inhibits SERCA, a calcium pump which is critical for cells to maintain their membrane potential. Untargeted, the drug is far too toxic to use medically. But you can slow levitra price down this change by leading a stress free life and taking an anti-impotency drug. Drink plentiful water discount buy viagra and reduced the amount of sodium you take all through the day. Normal atmospheric pressure (14.7psi at sea level) outside the cylinder and near the pubic bone area will force blood to rush in to satisfy the differences between that pressure and the one inside the cylinder. buy cialis no prescription Thus by using this medication every man will be able to knock off impotence from their life. online cialis But the authors showed that by combining it with the PSMA targeting peptide, they were able to make a prodrug, G202, which achieved “substantial tumor regression against a panel of human cancer xenografts in vivo at doses that were minimally toxic to the host.” These results appeared in the June 28, 2012, issue of Science Translational Medicine. G202 is being developed by GenSpera Inc. The drug is currently in Phase I trials.

See the reprint click here…